Lentivirus Vector for Persistent Beta-Globin Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for beta-thalassemia and sickle cell disease, such as blood transfusions and hematopoietic stem cell transplantation, come with significant risks and limitations, including iron overload, graft-versus-host disease, and variable patient responses, highlighting the need for more effective and safer therapeutic options.
Innovation Solution
Development of a lentivirus vector comprising a nucleotide sequence encoding the β-globin gene with a threonine to glutamine substitution at position 88, specifically designed to express the β-globin gene in erythroid cells, using a viral genome structure that includes long terminal repeats, HIV-1 psi, RRE, human β-globin promoter, LCR, enhancer sequences, and SV40 PolyA Signal, for persistent expression and targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If blood transfusions are administered to treat beta-thalassemia, then patient survival is improved, but iron overload and life-threatening complications occur
Solution Approach 1:
The patent extracts and delivers only the functional beta-globin gene to hematopoietic stem cells, separating the therapeutic function from the harmful effects of repeated transfusions. The lentivirus vector carries only the necessary gene sequence (HBB gene with T88Q mutation) to correct the underlying defect, eliminating the need for continuous external transfusions that cause iron overload.
Solution Approach 2:
The gene therapy enables patients to produce their own functional beta-globin chains through transduced hematopoietic stem cells. The corrected genes integrate into the patient's bone marrow and continuously produce functional hemoglobin, making the patient's body self-sufficient and eliminating dependence on external blood transfusions.
2Reliability
If hematopoietic stem cell transplantation is performed to cure beta-thalassemia, then definitive cure is achieved, but significant mortality and morbidity occur due to GVHD and chemotherapy requirements
Solution Approach 1:
The patent extracts only the therapeutic beta-globin gene from the lentivirus vector, eliminating the need for complete stem cell transplantation. The vector contains minimal essential elements (LTRs, psi, RRE, promoter, enhancer, polyA signal) without requiring donor stem cells, thereby avoiding GVHD and intensive chemotherapy conditioning.
Solution Approach 2:
The lentivirus vector acts as an intermediary carrier that delivers the therapeutic gene to patient's own hematopoietic stem cells. This intermediate delivery mechanism avoids the need for allogeneic stem cell transplantation and its associated risks of GVHD, while still achieving gene correction and functional cure.
3Reliability
If frequent blood transfusions are administered to manage beta-thalassemia, then patient survival is maintained, but healthcare costs increase significantly
Solution Approach 1:
The gene therapy establishes self-sufficiency by enabling patients to produce functional beta-globin chains continuously from their own corrected hematopoietic stem cells. This eliminates the need for lifelong expensive transfusions, reducing healthcare costs while maintaining survival.
Solution Approach 2:
The lentivirus-mediated gene correction provides continuous production of functional beta-globin chains throughout the patient's life. The integrated gene expression is sustained and continuous, replacing the intermittent and costly transfusion regimen with a one-time therapeutic intervention that maintains survival indefinitely.
Data Source
AI summary
The invention provides persistent expression of β-globin gene by using cell and/or gene therapy based administration of nucleotide sequence encoding β-globin gene to treat thalassemia and sickle cell anemia. Lentivirus (LV) based viral vector system containing an expression cassette of β-globin gene. Whereas, the lentivirus particle is packed with genes expressing functional β-globin gene in erythroid cell lineage specifically.